Tag: NSCLC,Non-Small Cell Lung Cancer,Press Releases,Series E Financing,Veristrat,liquid biopsy,molecular diagnostic,personalized medicine,serum protein test
-
Biodesix Closes Series E Financing
Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed an $8.3 million Series E preferred equity financing. New funds accounted for $4.3 million of the round and the remaining $4 million came from the conversion of a convertible note. Existing Biodesix shareholders provided all of the…